CN116375877A - 一种细胞穿透抗菌肽pw2及其制备方法和应用 - Google Patents
一种细胞穿透抗菌肽pw2及其制备方法和应用 Download PDFInfo
- Publication number
- CN116375877A CN116375877A CN202211532078.9A CN202211532078A CN116375877A CN 116375877 A CN116375877 A CN 116375877A CN 202211532078 A CN202211532078 A CN 202211532078A CN 116375877 A CN116375877 A CN 116375877A
- Authority
- CN
- China
- Prior art keywords
- cell penetrating
- peptide
- antibacterial peptide
- antibacterial
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims abstract description 57
- 230000000149 penetrating effect Effects 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims abstract description 52
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 15
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 7
- 210000002540 macrophage Anatomy 0.000 claims abstract description 7
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims abstract description 6
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims abstract description 6
- 108700003968 Human immunodeficiency virus 1 tat peptide (49-57) Proteins 0.000 claims abstract description 4
- NQIHMZLGCZNZBN-PXNSSMCTSA-N Trp-Trp Chemical group C1=CC=C2C(C[C@H](NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)N)C(O)=O)=CNC2=C1 NQIHMZLGCZNZBN-PXNSSMCTSA-N 0.000 claims abstract description 4
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 claims abstract description 3
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 claims abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 230000003834 intracellular effect Effects 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 230000002949 hemolytic effect Effects 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 3
- 239000007790 solid phase Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 claims description 2
- 238000004007 reversed phase HPLC Methods 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 abstract description 10
- 244000144972 livestock Species 0.000 abstract description 6
- 230000003115 biocidal effect Effects 0.000 abstract description 4
- 241000192125 Firmicutes Species 0.000 abstract description 3
- 238000001308 synthesis method Methods 0.000 abstract 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 16
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 16
- 239000000243 solution Substances 0.000 description 13
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 229930182555 Penicillin Natural products 0.000 description 8
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 229940049954 penicillin Drugs 0.000 description 8
- 244000052769 pathogen Species 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 108010036176 Melitten Proteins 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000003875 Wang resin Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000005142 microbroth dilution method Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000001196 time-of-flight mass spectrum Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明提供一种细胞穿透抗菌肽PW2及其制备方法和应用，属于农业畜牧兽医应用领域，细胞穿透抗菌肽PW2的序列如SEQ ID No.1所示；合成方法示意如下：通过成对Trp‑Trp基序与Pro排列来促进细胞穿透抗菌肽的抗菌活性，其序列为PWWPPWWP；衍生自HIV的细胞穿透肽TAT的氨基酸序列为RKKRRQRRR；两者通过三甘氨酸连接体GGG相连，并命名为PW2。本发明的细胞穿透抗菌肽PW2对革兰氏阴性菌和革兰氏阳性菌具有较高的抑菌活性，能够杀灭小鼠巨噬细胞RAW264.7内的金黄色葡萄球菌，使其具备成为饲用抗生素替代物的潜力。
Description
技术领域
本发明属于农业畜牧兽医应用领域，具体涉及一种细胞穿透抗菌肽PW2及其制备方法和应用。
背景技术
细胞内感染是慢性疾病的代表性杀手，病原体潜入细胞内可逃避机体免疫防御和清除的一系列作用，通常对宿主细胞毒性较低，以保证其长期隐匿于细胞内，因此在机体内不断生长和繁殖，并可在畜禽动物之间水平传播，在适当时机或当畜禽免疫力减弱时便发作，严重时可危及生命。细胞内感染病原体对畜牧生产造成了严重的危害，例如，无乳链球菌侵袭奶牛乳腺细胞后会造成奶牛泌乳量下降、乳品质降低等危害。猪伤寒沙门氏菌侵袭断奶仔猪肠道上皮细胞也会导致仔猪免疫力下降、降低采食量和生长性能。因此，解决细胞内感染在畜牧兽医领域具有极为广阔的市场应用前景。
虽然青霉素在目前是一种极为有效的抗感染药物，但是青霉素无法转导进入细胞内部来清除胞内细菌。此外，随着农业农村部194号公告的颁布，饲料中已全面禁用饲用抗生素。因此，迫切寻找一种能够清除胞内细菌的生物分子。抗菌肽是生物体内广泛存在的具有抗菌活性的小分子多肽，对真菌、病毒、寄生虫和癌细胞也具有杀伤作用。现需要一种能够清除细胞内细菌的高效细胞穿透抗菌肽，为饲用型抗菌肽的研发提供理论基础和技术支持。
发明内容
基于以上问题，本发明的目的在于公开一种细胞穿透抗菌肽PW2，该抗菌肽PW2是一种衍生自HIV的细胞穿透肽TAT和抗菌肽杂合形成的细胞穿透抗菌肽，其目的是能够穿透哺乳动物细胞并清除胞内病原体，克服青霉素无法解决的胞内感染的难题，使其拥有成为抗生素替代物的潜力。
本发明的目的是这样实现的：一种细胞穿透抗菌肽PW2，其氨基酸序列如SEQIDNo.1所示，其C端酰胺化。
本发明的另一目的是提供如上所述的一种细胞穿透抗菌肽PW2的制备方法，如下：通过成对Trp-Trp基序与Pro排列来促进细胞穿透抗菌肽的抗菌活性，其序列为PWWPPWWP；衍生自HIV的细胞穿透肽TAT的氨基酸序列为RKKRRQRRR；两者通过三甘氨酸连接体GGG相连；采用固相化学合成法得到肽树脂，将得到的肽树脂经过TFA切割后，得到多肽，其序列如SEQ ID No.1所示，经过反相高效液相色谱纯化和质谱鉴定后，即完成该多肽的制备；再经过抗菌活性检测、溶血活性的测定、细胞内杀菌能力的测定，最后命名为细胞穿透抗菌肽PW2。
本发明的另一目的是提供如上所述的一种细胞穿透抗菌肽PW2在制备治疗革兰氏阴性菌和/或革兰氏阳性菌感染性的疾病的药物中的应用。
进一步的，如上所述的应用，所述的抗菌肽PW2能够杀灭细胞内的金黄色葡萄球菌。
进一步的，如上所述的应用，所述的抗菌肽PW2能够杀灭小鼠巨噬细胞RAW264.7内的金黄色葡萄球菌。
本发明的有益效果及优点如下：本发明杂合了细胞穿透肽TAT和抗菌肽，对形成的细胞穿透抗菌肽PW2进行生物学活性检测，发现其不但对大肠杆菌、金黄色葡萄球菌、鼠伤寒沙门氏菌等6种菌种有高效的抑制作用，而且具备较低的溶血毒性，该细胞穿透抗菌肽在128μM的浓度下仅造成2.16％的红细胞溶血。另外，该细胞穿透抗菌肽具有杀灭小鼠巨噬细胞RAW264.7内金黄色葡萄球菌的能力，而青霉素无法杀灭胞内细菌，其已具备成为抗生素替代物和饲用型细胞穿透抗菌肽的发展潜力。
附图说明
图1为本发明的细胞穿透抗菌肽PW2的高效液相色谱图。
图2为本发明的细胞穿透抗菌肽PW2的基质辅助激光解吸/电离飞行时间质谱图。
图3为本发明的细胞穿透抗菌肽PW2和蜂毒素ME的溶血活性图。
图4为本发明的细胞穿透抗菌肽PW2和青霉素的细胞内杀菌图。
具体实施方式
下面根据说明书附图举例对本发明做进一步的说明:
实施例1
细胞穿透抗菌肽的设计
以成对Trp-Trp基序与Pro的排列，即PWWPPWWP的多肽，以及衍生自HIV的TAT，即RKKRRQRRR为细胞穿透肽，杂合得到细胞穿透抗菌肽，命名为PW2。细胞穿透抗菌肽的序列如表1所示。
表1细胞穿透抗菌肽的氨基酸序列。
PW2的正电荷数为+9，疏水值为0.181。该细胞穿透抗菌肽不仅可以抑制多种病原微生物的生长，而且对人血红细胞没有毒性。重要的是，该细胞穿透抗菌肽能够杀灭侵染进入小鼠巨噬细胞RAW264.7的金黄色葡萄球菌，具有开发为抗生素替代物的潜力。
实施例2：
固相化学合成法合成细胞穿透抗菌肽
1、细胞穿透抗菌肽的制备从C端到N端逐一进行，通过多肽合成仪来完成。首先将Fmoc-X(X是每个抗菌肽的C端第一个氨基酸)接入到Wang树脂，然后脱去Fmoc基团后得到X-Wang树脂；再将Fmoc-Y-Trt-OH(9-芴甲氧羧基-三甲基-Y，Y为每个抗菌肽C端第二个氨基酸)；按照这个程序依次从C端合成到N端，直至合成完毕，得到脱去Fmoc基团的侧链保护的树脂；
2、在上述得到的肽树脂中，加入切割试剂，20℃避光下反应2h，过滤；沉淀TFA(三氟乙酸)洗涤，将洗液与上述滤液混合，旋转蒸发仪浓缩，再加入10倍左右体积的预冷无水乙醚，-20℃沉淀3h，析出白色粉末物，以2500g离心10min，收集沉淀，再用无水乙醚洗涤沉淀，真空干燥，得到多肽，其中切割试剂由TFA、水和TIS(三异丙基氯硅烷)按照质量比95:2.5:2.5混合而成；
3、使用0.2M的硫酸钠(磷酸调节至pH7.5)进行柱平衡30min，用90％乙腈水溶液溶解多肽，过滤，C18反相常压柱，采用梯度洗脱(洗脱剂为甲醇和硫酸钠水溶液按照体积比为30:70～70:30混合)，流速为1mL/min，检测波为220nm，收集主峰，冻干；再利用反相C18柱进一步纯化，洗脱液A为0.1％TFA/水溶液；洗脱液B为0.1％TFA/乙腈溶液，洗脱浓度为25％B～40％B，洗脱时间为12min，流速为1mL/min，再同上收集主峰，冻干；
4、抗菌肽的鉴定：将上述得到的抗菌肽经过电喷雾质谱法分析，质谱图中显示的分子量(如图1、2所示)与表1中的理论分子量基本一致，抗菌肽的纯度大于95％。
实施例3：
1、抗菌活性的测定：利用微量肉汤稀释法测定细胞穿透抗菌肽PW2和蜂毒素ME的最小抑菌浓度。以2mg/ml的BSA(含0.01％乙酸)作为稀释液，使用二倍稀释法依次配置系列梯度的抗菌肽溶液。取上述溶液100μL置于96孔细胞培养板中，然后分别添加等体积的待测菌液(～105个/mL)于各孔中。分别设置阳性对照(含有菌液而不含有抗菌肽)和阴性对照(既不含菌液也不含抗菌肽)。37℃恒温培养14-18h，用酶标仪在492nm(OD492nm)处测定光吸收值，确定最小抑菌浓度。检测结果见表2。
表2细胞穿透抗菌肽PW2的抑菌活性
通过表2可以看出，PW2对于革兰氏阴性菌(E.coli 25922,S.typhimurium 14028和S.pullorum 7913)和革兰氏阳性菌(S.aureus 29213,S.aureus 12228和S.aureus43300)表现出较高的抑菌活性。
2、溶血活性的测定：采集人的新鲜血液1mL，肝素抗凝后溶解到2mL的PBS溶液中，3000rpm离心10min，收集红细胞；用PBS溶液洗涤3遍，再用10mL PBS溶液重悬；取50μL红细胞悬液与50μL不同浓度的抗菌肽溶液混合均匀，在37℃培养箱内恒温孵育1h；随后在4℃，3000rpm下离心10min；取出上清液用酶标仪在570nm处测定光吸收值。其中50μL红细胞加50μLPBS溶液作为阴性对照，50μL红细胞加50μL的0.1％ Tritonx-100作为阳性对照。最小溶血浓度是抗菌肽引起10％溶血率时的抗菌肽浓度，检测结果见图3。通过图3可以看出，PW2在检测范围内未表现出溶血活性，在128μM浓度下造成2.16％的红细胞溶血，未能引起10％的红细胞溶血，与对照组蜂毒素呈显著性差异。通过表3可以看出，PW2的选择指数高于具有强毒性的蜂毒素ME，表明PW2具备开发成为饲用型细胞穿透抗菌肽的潜力。
表3抗菌肽的MHC(μM)、GM(μM)和SI值
3、细胞内杀菌能力的测定：复苏液氮中的小鼠巨噬细胞RAW264.7，以细胞长满瓶底(80％-90％)为宜。使用无菌PBS溶液清洗并重悬细胞3次，并用胰酶消化液对细胞消化处理，使其在瓶底脱落，随后用完全培养基冲洗，获得单个细胞悬液，同时在24孔板中填入1.5mL终浓度约为2×105的细胞悬液。细胞悬液在37℃，5％ CO2的环境下培养24h，使其在孔板底贴壁。收集金黄色葡萄球菌悬浊液并调整至浓度OD600nm为0.4，随后取出500μl细菌悬浊液加入到24孔板的每个孔中。细胞在37℃，5％ CO2的环境下被细菌侵染1h，随后用无菌PBS溶液清洗3次，加入终浓度为100μg/mL的庆大霉素和终浓度为5μg/mL的青霉素，继续在37℃，5％ CO2的环境下孵育1h以杀灭细胞外未侵染的细菌。孵育结束后用无菌PBS溶液清洗3次，加入终浓度为16μM的细胞穿透抗菌肽PW2，以及终浓度为5μg/mL的青霉素作为对照组，继续孵育4h。待孵育结束后，用无菌PBS溶液清洗3次，加入0.025％的Tritonx-100裂解细胞。将裂解液均匀地涂布在MHA固体培养基上，在37℃下培养18-24h后计算细菌存活率。通过图4可以看出，经过细胞穿透抗菌肽PW2处理后，小鼠巨噬细胞RAW246.7内金黄色葡萄球菌的负载量降低到20％以下，而青霉素处理组几乎没有杀灭细菌，表明细胞穿透抗菌肽PW2具备杀灭细胞内病原体的能力。
Claims (5)
1.一种细胞穿透抗菌肽PW2，其特征在于，氨基酸序列如SEQ ID No.1所示,其C端酰胺化。
2.根据权利要求1所述的一种细胞穿透抗菌肽PW2的制备方法，其特征在于，方法如下：通过成对Trp-Trp基序与Pro排列来促进细胞穿透抗菌肽的抗菌活性，其序列为PWWPPWWP；衍生自HIV的细胞穿透肽TAT的氨基酸序列为RKKRRQRRR；两者通过三甘氨酸连接体GGG相连；采用固相化学合成法得到肽树脂，将得到的肽树脂经过TFA切割后，得到多肽，其序列如SEQ ID No.1所示，经过反相高效液相色谱纯化和质谱鉴定后，即完成该多肽的制备；再经过抗菌活性检测、溶血活性的测定、细胞内杀菌能力的测定，最后命名为细胞穿透抗菌肽PW2。
3.根据权利要求1所述的一种细胞穿透抗菌肽PW2在制备治疗革兰氏阴性菌和/或革兰氏阳性菌感染性的疾病的药物中的应用。
4.根据权利要求3所述的应用，其特征在于：所述的抗菌肽PW2能够杀灭细胞内的金黄色葡萄球菌。
5.根据权利要求4所述的应用，其特征在于：所述的抗菌肽PW2能够杀灭小鼠巨噬细胞RAW264.7内的金黄色葡萄球菌。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211532078.9A CN116375877B (zh) | 2022-12-01 | 2022-12-01 | 一种细胞穿透抗菌肽pw2及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211532078.9A CN116375877B (zh) | 2022-12-01 | 2022-12-01 | 一种细胞穿透抗菌肽pw2及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116375877A true CN116375877A (zh) | 2023-07-04 |
| CN116375877B CN116375877B (zh) | 2023-10-27 |
Family
ID=86971777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211532078.9A Active CN116375877B (zh) | 2022-12-01 | 2022-12-01 | 一种细胞穿透抗菌肽pw2及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116375877B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117285599A (zh) * | 2023-10-11 | 2023-12-26 | 东北农业大学 | 一种抗胞内细菌的细胞穿透型抗菌肽5vt及其制备方法和应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001055423A1 (fr) * | 2000-01-26 | 2001-08-02 | Biodoor Gene Technology Ltd. Shanghai | Nouveau polypeptide, proteine pwwp humaine 58, et polynucleotide codant pour ce polypeptide |
| EP1262556A2 (en) * | 2001-06-01 | 2002-12-04 | Fundacao de Amparo a Pesquisa do Estado de Sao Paolo | Antimicrobial peptides and method for identifying and using such peptides |
| WO2009154264A1 (ja) * | 2008-06-20 | 2009-12-23 | 学校法人福岡大学 | ペプチド |
| CN106749559A (zh) * | 2016-11-23 | 2017-05-31 | 郑州大学 | 一种基于细胞穿膜肽Tat(49‑57)的抗菌肽及其合成方法 |
| CN111518168A (zh) * | 2020-03-30 | 2020-08-11 | 东北农业大学 | 一种衍生自肉食杆菌素的抗菌肽及其制备方法和应用 |
| CN113603748A (zh) * | 2021-07-09 | 2021-11-05 | 东北农业大学 | 一种β-折叠抗菌肽HINGE-RV及其制备方法和应用 |
-
2022
- 2022-12-01 CN CN202211532078.9A patent/CN116375877B/zh active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001055423A1 (fr) * | 2000-01-26 | 2001-08-02 | Biodoor Gene Technology Ltd. Shanghai | Nouveau polypeptide, proteine pwwp humaine 58, et polynucleotide codant pour ce polypeptide |
| EP1262556A2 (en) * | 2001-06-01 | 2002-12-04 | Fundacao de Amparo a Pesquisa do Estado de Sao Paolo | Antimicrobial peptides and method for identifying and using such peptides |
| WO2009154264A1 (ja) * | 2008-06-20 | 2009-12-23 | 学校法人福岡大学 | ペプチド |
| CN106749559A (zh) * | 2016-11-23 | 2017-05-31 | 郑州大学 | 一种基于细胞穿膜肽Tat(49‑57)的抗菌肽及其合成方法 |
| CN111518168A (zh) * | 2020-03-30 | 2020-08-11 | 东北农业大学 | 一种衍生自肉食杆菌素的抗菌肽及其制备方法和应用 |
| CN113603748A (zh) * | 2021-07-09 | 2021-11-05 | 东北农业大学 | 一种β-折叠抗菌肽HINGE-RV及其制备方法和应用 |
Non-Patent Citations (3)
| Title |
|---|
| CHRISTOPHE MARCHAND等: "Covalent binding of the natural antimicrobial peptide indolicidin to DNA abasic sites", NUCLEIC ACIDS RESEARCH, vol. 34, no. 18, pages 5157 - 5165 * |
| 刘又铭;陈璐;宋倩倩;吴超男;张海文;: "不同动物源抗菌肽对大肠杆菌杀菌机制比较研究", 饲料研究, no. 07, pages 72 - 76 * |
| 王婧;刁小龙;陈晓兰;王帅兵;陈海峰;张龙;: "抗菌肽Indolicidin的研究进展", 江苏农业学报, no. 04, pages 949 - 954 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117285599A (zh) * | 2023-10-11 | 2023-12-26 | 东北农业大学 | 一种抗胞内细菌的细胞穿透型抗菌肽5vt及其制备方法和应用 |
| CN117285599B (zh) * | 2023-10-11 | 2024-04-09 | 东北农业大学 | 一种抗胞内细菌的细胞穿透型抗菌肽5vt及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116375877B (zh) | 2023-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111423501B (zh) | 一种衍生自蝎毒的抗菌肽及制备方法和应用 | |
| CN109232717B (zh) | 一种针对革兰氏阴性菌靶向抗菌肽及制作方法与应用 | |
| CN111533786B (zh) | 色氨酸和精氨酸跨链交互作用的β发卡抗菌肽及制备方法 | |
| CN111518168B (zh) | 一种衍生自肉食杆菌素的抗菌肽及其制备方法和应用 | |
| CN116375877B (zh) | 一种细胞穿透抗菌肽pw2及其制备方法和应用 | |
| CN115960261A (zh) | 色氨酸和苯丙氨酸跨链交互β-发卡抗菌肽WFL及其制备方法和应用 | |
| CN113754784A (zh) | 一种细胞穿透抗菌肽及其应用 | |
| CN117924424B (zh) | 基于D型氨基酸跨链交互作用的β-发卡抗菌肽及制备方法和应用 | |
| CN113549137B (zh) | 一种靶向革兰氏阴性菌的富脯氨酸抗菌肽Pyr-2及其制备方法与应用 | |
| CN111533787B (zh) | 一种线性抗菌肽及其制备方法和应用 | |
| CN113214355B (zh) | 一种专杀真菌的抗菌肽gl4w及其制备方法和应用 | |
| CN115536737A (zh) | 眼镜王蛇抗菌肽oh-cath30在抗水产动物致病菌中的应用 | |
| CN111533781B (zh) | 非特异受体结合型真菌靶向抗菌肽及其制备方法和应用 | |
| CN111647044B (zh) | 一种富含苯丙氨酸抗菌肽及其制备方法和应用 | |
| CN109705195B (zh) | 一种大肠杆菌靶向抗菌肽ki-qk及制备方法和应用 | |
| CN110294809B (zh) | 靶向金黄色葡萄球菌抗菌肽s2及其制备方法和应用 | |
| CN115785220B (zh) | 一种高蛋白酶稳定性色氨酸富集抗菌肽及其制备方法和应用 | |
| CN111253474A (zh) | 一种抗菌肽rg-27及其应用 | |
| CN113603748B (zh) | 一种β-折叠抗菌肽HINGE-RV及其制备方法和应用 | |
| CN113956340A (zh) | 一种衍生自羊源抗菌肽rlr及其制备方法和应用 | |
| CN116478265B (zh) | 一种衍生自猪肝脏抗菌肽tjh及其制备方法和应用 | |
| CN116693621B (zh) | 抑制革兰氏阴性菌的窄谱抗菌肽pc及其制备方法和应用 | |
| CN116284250B (zh) | 耐蛋白酶水解的高稳定抗菌肽hw及其制备方法和应用 | |
| CN115925990B (zh) | 一种衍生自猪导管素的抗菌肽及其制备方法和应用 | |
| CN116041476B (zh) | 一种衍生自猪肝脏表达抗菌肽malk及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |